Study for the Prevention of Ascites (SPA): comparison of fixed doses of SR121463B [satavaptan] versus placebo in the reduction of recurrence of cirrhotic ascites

Trial Profile

Study for the Prevention of Ascites (SPA): comparison of fixed doses of SR121463B [satavaptan] versus placebo in the reduction of recurrence of cirrhotic ascites

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2007

At a glance

  • Drugs Satavaptan; Spironolactone
  • Indications Ascites
  • Focus Therapeutic Use
  • Acronyms SPA
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top